Novartis paid Takeda $3.4 billion for its FDA-approved dry eye drug Xiidra during the Japanese pharma’s merger with Shire in 2019, outlining the sales potential in this market niche. But with ...
Shire has launched its dry eye treatment Xiidra (lifitegrast) in the US, a drug the company hopes will achieve blockbuster status. The Dublin-based, London-listed company said Xiidra is available ...
Pre-tax losses at the main Irish unit of eye care product firm Bausch + Lomb increased by 4.5% to $959.7m (€925m) in 2023.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback